科伦博泰生物-B(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06990 科伦博泰生物-B

交易中 05-29 15:20:53

159.600

-6.400

-3.86%

最高172.000	最低156.100	成交量39.60万
今开172.000	昨收166.000	日振幅9.58%
总市值355.66亿	流通市值207.92亿	总股本2.23亿
成交额6,366万	换手率0.30%	流通股本1.30亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06990","market":"HK","secType":"STK","nameCN":"科伦博泰生物-B","latestPrice":159.6,"timestamp":1716967222536,"preClose":166,"halted":0,"volume":396000,"delay":0,"floatShares":130273005,"shares":222844099,"eps":-3.0578134,"marketStatus":"交易中","marketStatusCode":2,"change":-6.4,"latestTime":"05-29 15:20:53","open":172,"high":172,"low":156.1,"amount":63664355,"amplitude":0.095783,"askPrice":159.9,"askSize":100,"bidPrice":159.6,"bidSize":1500,"shortable":3,"etf":0,"ttmEps":-3.0578135095905177,"exchange":"SEHK","tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1716970200000},"adr":0,"listingDate":1689004800000,"adjPreClose":166,"openAndCloseTimeList":[[1716946200000,1716955200000],[1716958800000,1716969600000]],"volumeRatio":0.752842,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06990/wiki","defaultTab":"wiki","newsList":[{"id":"2439459618","title":"科伦博泰生物-B(06990)下跌5.3%，报157.2元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2439459618","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2439459618?lang=zh_cn&edition=full","pubTime":"2024-05-29 13:30","pubTimestamp":1716960654,"startTime":"0","endTime":"0","summary":"5月29日，科伦博泰生物-B盘中下跌5.3%，截至13:30，报157.2元/股，成交3962.55万元。四川科伦博泰生物医药股份有限公司是一家专注于创新药物研发、制造及商业化的生物医药公司，主要致力于内部开发差异化的治疗方法，以支持提高现有的医疗健康水平。截至2023年年报，科伦博泰生物-B营业总收入15.4亿元、净利润-5.74亿元。5月28日，太平洋首次给予买入评级,目标价226港元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/05/29133040813045.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2439599833","title":"科伦博泰生物－Ｂ(06990)股价下跌5.241%，现价港币$157.3","url":"https://stock-news.laohu8.com/highlight/detail?id=2439599833","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2439599833?lang=zh_cn&edition=full","pubTime":"2024-05-29 13:30","pubTimestamp":1716960600,"startTime":"0","endTime":"0","summary":"[下跌股]科伦博泰生物－Ｂ(06990) 股价在下午01:30比前收市价下跌5.241%，现股价为港币$157.3。至目前为止，今日最高价为$172.0，而最低价为$157.3。总成交量为24.4万股，总成交金额为港币$3.952千万。","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180126135515084_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180126135515084_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2405292254/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2438329143","title":"科伦博泰生物－Ｂ(06990)ADC商业化在即，携手默沙东剑指Biopharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2438329143","media":"太平洋证券","top":-1,"share":"https://www.laohu8.com/m/news/2438329143?lang=zh_cn&edition=full","pubTime":"2024-05-28 18:17","pubTimestamp":1716891444,"startTime":"0","endTime":"0","summary":"ADC风口之上，科伦博泰平台优势明显ADC正在开启广谱抗肿瘤模式，有望引领精准化疗新时代，成为肿瘤治疗格局的改变者。科伦博泰作为先行者，已成功构建OptiDC研发平台，4款ADC处于临床研究阶段，多款处于临床前研究阶段。科伦博泰ADC携手默沙东，国际化布局领先当前国内支付环境下，创新药出海已成必选项。ADC和PD-1强强联合有望为科伦博泰带来不菲的海外收入提成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405281830439ef8d272&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405281830439ef8d272&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2438197073","title":"港股概念追踪 | ADC药物进入加速期   机构看好创新药产业技术驱动周期（附概念股）","url":"https://stock-news.laohu8.com/highlight/detail?id=2438197073","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2438197073?lang=zh_cn&edition=full","pubTime":"2024-05-28 13:39","pubTimestamp":1716874750,"startTime":"0","endTime":"0","summary":"ADC药物进入加速期，多个临床前研究发布，创新程度提升。中信建投证券研究看好ADC药物带动创新药行业进入新周期。恒瑞医药、科伦博泰、信达生物、百利天恒、荣昌生物、再鼎医药、康宁杰瑞、普方生物、启德医药、映恩生物、华东医药等公司发布重要的ADC药物临床前及临床研究数据，涵盖多种实体瘤，显示出了良好的药物疗效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1126915.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2438385154","title":"科伦博泰生物-B(06990.HK)：SKB264肺癌积极数据兑现 国内商业化在即","url":"https://stock-news.laohu8.com/highlight/detail?id=2438385154","media":"中金公司","top":-1,"share":"https://www.laohu8.com/m/news/2438385154?lang=zh_cn&edition=full","pubTime":"2024-05-27 19:32","pubTimestamp":1716809526,"startTime":"0","endTime":"0","summary":"本次ASCO大会，SKB264 公布单药治疗后线TNBC的积极III期数据，结果显示与对照组化疗相比，接受SKB264 单药治疗的mPFS有效延长3.4 个月，证实了SKB264 在TNBC中的积极治疗疗效。公司预计SKB264 后线治疗TNBC有望在2H24 国内获批上市。科伦博泰当前正在开展SKB264 单药治疗一线PD-L1 阴性TNBC的国内III期临床，海外MSD已开展MK2870 联合K药新辅助治疗TNBC的全球III期临床。多款产品有望年内上市，科伦博泰国内即将进入商业化兑现期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405271932109568a941&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405271932109568a941&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2438740488","title":"【券商聚焦】招银国际：中国医药行业有望回归健康增长 续看好创新药和器械龙头以及高成长医疗消费个股","url":"https://stock-news.laohu8.com/highlight/detail?id=2438740488","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2438740488?lang=zh_cn&edition=full","pubTime":"2024-05-27 15:36","pubTimestamp":1716795375,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招银国际表示，年初至今，MSCI中国医疗指数下跌21.4%，大幅跑输MSCI中国指数32.5%。MSCI中国医疗指数自4月19日低点以来仅反弹9%；目前行业指数的动态市盈率为26.3倍，仍低于12年历史均值。该行预计，随着行业支持性政策陆续落地、行业监管常态化进行，中国医药行业有望回归健康增长。该行继续看好创新药和器械龙头以及高成长医疗消费个股。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/ZmQxNzMzMGZkNTNkZDQwNzE0NzM5MzEwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZmQxNzMzMGZkNTNkZDQwNzE0NzM5MzEwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1937580","is_publish_highlight":false,"gpt_icon":0},{"id":"2438847383","title":"科伦博泰生物-B(06990)下跌5.0%，报167.1元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2438847383","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2438847383?lang=zh_cn&edition=full","pubTime":"2024-05-27 10:10","pubTimestamp":1716775839,"startTime":"0","endTime":"0","summary":"5月27日，科伦博泰生物-B(06990)盘中下跌5.0%，截至10:10，报167.1元/股，成交749.86万元。四川科伦博泰生物医药股份有限公司是一家专注于创新药物研发、制造及商业化的生物医药公司，主要致力于内部开发差异化的治疗方法，以支持提高现有的医疗健康水平。公司已建立涵盖全部主要药物开发功能的一体化能力，能够战略性地快速推进33款差异化且具有临床价值的资产管线，其中14款处于临床阶段，并已签署了九项对外许可协议，前期及里程碑付款合共高达118亿美元。截至2023年年报，科伦博泰生物-B营业总收入15.4亿元、净利润-5.74亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/05/27101040782005.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2438479508","title":"科伦博泰生物－Ｂ(06990)股价下跌5.173%，现价港币$166.8","url":"https://stock-news.laohu8.com/highlight/detail?id=2438479508","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2438479508?lang=zh_cn&edition=full","pubTime":"2024-05-27 10:09","pubTimestamp":1716775740,"startTime":"0","endTime":"0","summary":"[下跌股]科伦博泰生物－Ｂ(06990) 股价在上午10:09比前收市价下跌5.173%，现股价为港币$166.8。至目前为止，今日最高价为$179.9，而最低价为$166.8。总成交量为4.19万股，总成交金额为港币$721.185万。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180205152747204_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180205152747204_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD240527459/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2437948728","title":"港股异动 | 科伦博泰生物-B(06990)现涨超5% 公司将于ASCO上公布乳腺癌及肺癌药物研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2437948728","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2437948728?lang=zh_cn&edition=full","pubTime":"2024-05-24 09:36","pubTimestamp":1716514595,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科伦博泰生物-B现涨超5%，截至发稿，涨2.81%，报179.2港元，成交额1959.39万港元。消息面上，科伦博泰生物公布，将于5月31日至6月4日在美国伊利诺伊州芝加哥市举行的2024年美国临床肿瘤学会年会上，公布其抗TROP2 ADC芦康沙妥珠单抗用于既往接受过治疗的局部复发或转移性三阴性乳腺癌患者的3期研究结果。此外，于口头报告环节将展示芦康沙妥珠单抗联合KL-A167用于一线治疗晚期非小细胞肺癌患者的2期研究结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1125563.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2437728306","title":"科伦博泰生物-B(06990)上涨5.22%，报183.4元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2437728306","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2437728306?lang=zh_cn&edition=full","pubTime":"2024-05-24 09:33","pubTimestamp":1716514382,"startTime":"0","endTime":"0","summary":"5月24日，科伦博泰生物-B(06990)盘中上涨5.22%，截至09:33，报183.4元/股，成交1552.83万元。四川科伦博泰生物医药股份有限公司是一家专注于创新药物研发、制造及商业化的生物医药公司，主要致力于内部开发差异化的治疗方法，以支持提高现有的医疗健康水平。公司已建立涵盖全部主要药物开发功能的一体化能力，能够战略性地快速推进33款差异化且具有临床价值的资产管线，其中14款处于临床阶段，并已签署了九项对外许可协议，前期及里程碑付款合共高达118亿美元。截至2023年年报，科伦博泰生物-B营业总收入15.4亿元、净利润-5.74亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/05/24093340762886.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2437740642","title":"科伦博泰生物-B(06990.HK)将于医学年会公布乳腺癌及肺癌药物研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2437740642","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2437740642?lang=zh_cn&edition=full","pubTime":"2024-05-24 09:20","pubTimestamp":1716513600,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B公布，将于5月31日至6月4日在美国伊利诺伊州芝加哥市举行的2024年美国临床肿瘤学会年会上，公布其抗TROP2 ADC芦康沙妥珠单抗用于既往接受过治疗的局部复发或转移性三阴性乳腺癌患者的3期研究结果。此外，于口头报告环节将展示芦康沙妥珠单抗联合KL-A167用于一线治疗晚期非小细胞肺癌患者的2期研究结果。芦康沙妥珠单抗在临床阶段为公司与默沙东联合开发。(港股报价延迟最少十五分钟。沽空资料截至 2024-05-23 16:25。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20230904161536655_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20230904161536655_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1351806/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2437717782","title":"科伦博泰生物-B(06990)：核心产品芦康沙妥珠单抗(sac-TMT) 于2024年美国临床肿瘤学会年会上公布的研究成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2437717782","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2437717782?lang=zh_cn&edition=full","pubTime":"2024-05-24 06:23","pubTimestamp":1716503015,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物-B 发布公告，公司将在于2024年5月31日至6月4日于美利坚合众国伊利诺伊州芝加哥市举行的2024年美国临床肿瘤学会年会上，于当地时间2024年6月2日早上9:45至11:15举办的临床科学研讨会上公布其抗TROP2 ADC芦康沙妥珠单抗用于既往接受过治疗的局部复发或转移性三阴性乳腺癌患者的 3期研究结果。芦康沙妥珠单抗在临床阶段为公司与默沙东联合开发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1125496.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2436914182","title":"科伦博泰生物-B(06990): 发行364.86万股新股","url":"https://stock-news.laohu8.com/highlight/detail?id=2436914182","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2436914182?lang=zh_cn&edition=full","pubTime":"2024-05-17 20:00","pubTimestamp":1715947245,"startTime":"0","endTime":"0","summary":"快讯正文2024年5月16日，科伦博泰生物-B宣布，公司根据配售协议成功增发364.86万股，此举或将对公司股价产生重要影响。科伦博泰生物-B在资本市场的表现一直备受瞩目，此次增发无疑为公司的长期发展注入了新的活力。对投资者而言，科伦博泰生物-B的股价波动或将成为近期关注的焦点。科伦博泰生物-B的未来发展值得期待，投资者应密切关注公司的财务报告和市场动态，以把握最佳投资时机。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405172138168774a1cb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405172138168774a1cb&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2436997047","title":"科伦博泰生物-B(06990)5月16日发行364.86万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2436997047","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2436997047?lang=zh_cn&edition=full","pubTime":"2024-05-17 19:11","pubTimestamp":1715944293,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物-B(06990)发布公告，于2024年5月16日根据配售协议发行364.86万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1122749.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2435629767","title":"科伦博泰生物-B(06990)完成配售合共364.86万股 净筹约5.41亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2435629767","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2435629767?lang=zh_cn&edition=full","pubTime":"2024-05-16 16:59","pubTimestamp":1715849973,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物-B(06990)发布公告，配售事项的所有条件均已达成，且配售事项已于2024年5月16日完成。合共364.86万股配售股份已由配售代理根据配售协议的条款及条件，以每股股份150.00港元的配售价成功向不少于六名承配人配售。公告称，配售事项所得款项净额约为5.41亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1122020.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2435462683","title":"科伦博泰生物-B05月16日主力资金流出56万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2435462683","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2435462683?lang=zh_cn&edition=full","pubTime":"2024-05-16 16:17","pubTimestamp":1715847433,"startTime":"0","endTime":"0","summary":"05月16日, 科伦博泰生物-B股价跌1.65%，报收172.80元，成交金额1.04亿元，换手率0.48%，振幅7.46%，量比0.86。科伦博泰生物-B今日主力资金净流出56万元，连续3日净流出，上一交易日主力净流出414万元，今日环比减少86.47%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为50.00%，平均跌幅为4.06%。该股近5个交易日上涨6.00%，主力资金累计净流入586万元；近20日主力资金累计净流入9382万元，其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405161618358b0e2687&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405161618358b0e2687&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2435611121","title":"科伦博泰生物-B(06990)下跌5.07%，报166.8元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2435611121","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2435611121?lang=zh_cn&edition=full","pubTime":"2024-05-16 10:31","pubTimestamp":1715826670,"startTime":"0","endTime":"0","summary":"5月16日，科伦博泰生物-B(06990)盘中下跌5.07%，截至10:31，报166.8元/股，成交4842.15万元。四川科伦博泰生物医药股份有限公司是一家专注于创新药物研发、制造及商业化的生物医药公司，主要致力于内部开发差异化的治疗方法，以支持提高现有的医疗健康水平。公司已建立涵盖全部主要药物开发功能的一体化能力，能够战略性地快速推进33款差异化且具有临床价值的资产管线，其中14款处于临床阶段，并已签署了九项对外许可协议，前期及里程碑付款合共高达118亿美元。截至2023年年报，科伦博泰生物-B营业总收入15.4亿元、净利润-5.74亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/05/16103140665083.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2435188726","title":"医药行业第二次年度盛会临近，关注创新药研发进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2435188726","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2435188726?lang=zh_cn&edition=full","pubTime":"2024-05-16 08:56","pubTimestamp":1715820985,"startTime":"0","endTime":"0","summary":"ASCO年会将于5月31日至6月4日在芝加哥召开，此前于4月上旬召开的AACR也吸引了诸多国内知名药企、院校参与，公布的众多重磅临床数据带动医药行业关注度回升。国信证券提到，ASCO会议是每年临床数据展示的重要国际会议之一，近几年国内药企在该会议上的数据读出逐年增加，体现出国内药企的药物研发能力日渐增强。浙商证券提到，今年ASCO中国本土创新药企业多项数据入选口头摘要，快速口头摘要，临床科学研讨会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240516085742876e36e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240516085742876e36e1&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2435192659","title":"科伦药业刘革新：科伦已上岸","url":"https://stock-news.laohu8.com/highlight/detail?id=2435192659","media":"经济观察报","top":-1,"share":"https://www.laohu8.com/m/news/2435192659?lang=zh_cn&edition=full","pubTime":"2024-05-15 22:49","pubTimestamp":1715784580,"startTime":"0","endTime":"0","summary":"经济观察网 记者 张铃 “科伦现在已经上岸了。”在科伦药业（002422.SZ）5月14日发布的一份投资者关系活动记录表中，科伦药业董事长刘革新在被问及如何看待当前行业的低迷时说，行业的低迷不等于企业的低迷。科伦药业2023年业绩报告显示，其营收为215亿元，同比增长13%；净利润25亿元，同比增长44%。这是科伦药业自2019年之...","market":"hk","thumbnail":"https://inews.gtimg.com/om_ls/OpT5VekNIKqgZBRYeUZf5-RX6h9URb-0n6k7u3IDxet2MAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OpT5VekNIKqgZBRYeUZf5-RX6h9URb-0n6k7u3IDxet2MAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240515A0ANGR00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240515A0ANGR00","is_publish_highlight":false,"gpt_icon":0},{"id":"2435134810","title":"科伦博泰生物－Ｂ(06990)股价下跌8.889%，现价港币$172.2","url":"https://stock-news.laohu8.com/highlight/detail?id=2435134810","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2435134810?lang=zh_cn&edition=full","pubTime":"2024-05-13 15:30","pubTimestamp":1715585400,"startTime":"0","endTime":"0","summary":"[下跌股]科伦博泰生物－Ｂ(06990) 股价在下午03:30比前收市价下跌8.889%，现股价为港币$172.2。至目前为止，今日最高价为$189.2，而最低价为$172.2。总成交量为41.448万股，总成交金额为港币$7.483千万。","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180205152743541_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180205152743541_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2405131829/aamm-all-category","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://kelun-biotech.com","stockEarnings":[{"period":"1week","weight":-0.06},{"period":"1month","weight":-0.0119},{"period":"3month","weight":0.4968},{"period":"6month","weight":0.7566},{"period":"1year","weight":1.7393},{"period":"ytd","weight":0.6132}],"compareEarnings":[{"period":"1week","weight":-0.0208},{"period":"1month","weight":0.0663},{"period":"3month","weight":0.1381},{"period":"6month","weight":0.1043},{"period":"1year","weight":0.0146},{"period":"ytd","weight":0.104}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"四川科伦博泰生物医药股份有限公司是一家主要从事创新药业务的研发、生产和销售的中国公司。该公司主要从事生物药品、化学药品原料、化学药品制剂的研发、生产和销售。该公司的产品主要用于乳腺癌、非小细胞肺癌、胃肠道癌等非肿瘤疾病的治疗。","exchange":"SEHK","name":"科伦博泰生物-B","nameEN":"SKB BIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科伦博泰生物-B(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科伦博泰生物-B(06990)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科伦博泰生物-B,06990,科伦博泰生物-B股票,科伦博泰生物-B股票老虎,科伦博泰生物-B股票老虎国际,科伦博泰生物-B行情,科伦博泰生物-B股票行情,科伦博泰生物-B股价,科伦博泰生物-B股市,科伦博泰生物-B股票价格,科伦博泰生物-B股票交易,科伦博泰生物-B股票购买,科伦博泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科伦博泰生物-B(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科伦博泰生物-B(06990)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}